Michael Rawlins (Oct 27, p 1462)1 reviews Ben Goldacre's Bad Pharma as a long and often angry book that can repeat criticisms that are not new. For Rawlins, the book lacks equipoise-it fails to balance criticisms of big pharma with industry's benefits. Rawlins echoes the remark by Stephen Whitehead2 (Chief Executive Officer of the British Pharmaceutical Association) that it has become fashionable to criticise the pharmaceutical industry and overlook its contributions to medicine.
展开▼
